Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert

To report the outcome of treatment of non invasive ocular surface squamous neoplasia with topical mitomycin C as primary therapy

Search Title by author or title

Session Details

Session Title: Cornea: Medical

Session Date/Time: Tuesday 10/10/2017 | 08:00-10:30

Paper Time: 09:00

Venue: Room 3.6

First Author: : Y.Singhal INDIA

Co Author(s): :                        

Abstract Details

Purpose:

To report the outcome of treatment of non invasive ocular surface squamous neoplasia with topical Mitomycin C.

Setting:

Department of Ophthalmology, Sardar Patel Meical College and Associated Groups of hospital, Bikaner, Rajasthan, India

Methods:

Our study included 9 cases of localized non invasive ocular surface squamous neoplasia which were histopathologically confirmed by excisional biopsy.It was a prospective non- comparative interventional case series. After clinical examination and histopathological examination, diagnosis of Ocular surface squamous neoplasia was made. Patients were started on freshly prepared Mitomycin C 0.02% in form of eyedrop instilled QID and continued for three cycles with 2 weeks ON and 2 weeks OFF. Topical NSAID Flurbiprofen and artificial tears QID were also started. Patient was followed up after every 2 weeks till the completion of three cycles and and then monthly interval.

Results:

at the time of follow up at the end of one cycle, mass was reduced in size in all patients. At the end of third cycle there was complete regression of mass in all cases. Patients are still under follow up and there is no recurrence. Patients reported mild to moderate redness and irritation which was controlled with lubricants and NSAID. No serious ocular or systemic side effects were observed.

Conclusions:

Mitomycin C (0.02%) with 2 weeks on and 2weeks off is a well tolerable dose with no serious side effects for treatment of Ocular surface squamous neoplasia. Topical Mitomycin C (0.02%) may be used as a sole therapeutic treatment of non invasive Ocular surface squamous neoplasia with close on going follow- up.

Financial Disclosure:

NONE

Back to previous